CurePSP Awards Latest Pathway and Pipeline Grants and Urso Student Fellowship...
Studies seek to establish an early-stage blood biomarker, explore novel therapies and support the creation of a cohort of PSP and CBD patients in Argentina. NEW YORK, Sept. 28, 2023 /PRNewswire/ —...
View ArticleClik here to view.
CurePSP Recognizes Three Prominent Medical Institutions for Their Care for...
NEW YORK (October 5, 2023) /PRNewswire/ — CurePSP has announced the designation of three new CurePSP Centers of Care, bringing the total to 33 centers across the United States and Canada. Vanderbilt...
View ArticleClik here to view.
CurePSP Presents Two Scientific Posters at 2023 International Movement...
By Jessica Shurer, Director of Clinical Affairs and Advocacy at CurePSP More than 5,000 neurology professionals from 105 countries attended the Movement 2023 International Movement Disorder Society...
View ArticlePSP Care Partner Quoted in New York Times Article on Caregiving
A PSP care partner talked about her experience in a recent New York Times article titled “The Quiet Rage of Caregivers.” Jennifer Levine, whose father had PSP, talked about the range of emotions felt...
View ArticleClik here to view.
U.S. House of Representatives Passes the National Plan to End Parkinson’s Act!
CurePSP is thrilled that HR 2365, originally the National Plan to End Parkinson’s Act and now the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act, passed the...
View ArticleProtected: Neuro 2023 Private Access
This content is password protected. To view it please enter your password below: Password: The post Protected: Neuro 2023 Private Access appeared first on CurePSP.
View ArticleClik here to view.
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase...
– Largest ever PSP clinical trial will evaluate the efficacy and safety of AMX0035 in adults with PSP compared to placebo – Trial to enroll approximately 600 participants across the U.S., Canada,...
View ArticleAmylyx is starting to recruit for a phase III clinical trial
For PSP Patients and Care Partners: Amylyx is starting to recruit for a phase III clinical trial to evaluate the clinical safety, tolerability, and efficacy of a potential treatment for adults with...
View ArticleCurePSP Funds Collaborative Projects Focused on Care of Neurodegenerative...
NEW YORK, Jan. 9, 2024 /PRNewswire/ — CurePSP announced the recipients of their Collaborative Approaches to Resources, Education and Support (CARES) grants, marking the second year of the innovative...
View ArticleLeading Researchers and Representatives of Alzheimer’s Association, CurePSP...
In February 2022, leading international tau experts convened to share selected highlights of the paper, “Novel avenues of tau research,” during Tau 2022, the second international tau conference...
View Article
